Biogen Idec Inc., maker of the multiple sclerosis drugs Avonex, Tysabri and Tecfidera, bought rights to Japan's Eisai Co.'s experimental Alzheimer's disease medicines as it seeks to add treatments for brain disorders. Biogen will pay Eisai an ... Pharmaceutical Manufacturing Magazine, 8 hours ago
Eisai, Biogen Idec begin collaboration on Alzheimer's compounds - Drug Discovery News, 22 hours ago
Eisai, Biogen Idec ink collaboration to develop and commercialize Alzheimer€s disease drugs, E2609 & BAN2401 - PharmaBiz, 2 days ago
Eisai has said the sudden imposition of MAT on SEZ units has affected the company's financials and its scheme to supply certain free medicines to a public health programme run by WHO Sushmi Dey & Vrishti Beniwal | New Delhi March 4, 2014 Last Updated at 00:36 ...Business Standard, 4 days ago
Eisai Announces Initiation of a Phase 3 Trial of Eribulin Mesylate Injection Versus Weekly Paclitaxel in First and Second Lines of Metastatic Breast...
Eisai Announces Initiation of a Phase 3 Trial of Eribulin Mesylate Injection Versus Weekly Paclitaxel in First and Second Lines of Metastatic Breast Cancer By a News Reporter-Staff News Editor at Women's Health Weekly -- Eisai Inc. announced the ...4 Traders, 2 days ago Eisai Begins CAMELLIA-TIMI 61 Long-term Outcomes Study to Assess Cardiovascular and Metabolic Effects of Lorcaserin HCI CIV in Overweight/Obese... 4 Traders, 2 days ago Eisai starts Phase III breast cancer trial of eribulin mesylate versus paclitaxel Pharmaceutical Business Review, 4 days ago Eisai initiates Phase 3 Trial for metastatic breast cancer drug Pharmaceutical & Medical Packaging News, 1 week ago
The Federal Joint Committee (G-BA), the supreme decision-making body of the joint self-administration in the German health care system has confirmed that Eisai's epilepsy drug Fycompa (perampanel) may be submitted for re-benefit assessment at an ...PharmaBiz, 3 weeks ago Fycompa® (Perampanel) to be Resubmitted Early to German Federal Joint Committee (G-BA) for Additional Benefit Assessment Sys-Con Italia, 3 weeks ago Fycompa(R) (Perampanel) to be Resubmitted Early to German Federal Joint Committee (G-BA) for Additional Benefit Assessment Individual.com, 3 weeks ago
The 2 most recently introduced new agents for weight loss in the United States, lorcaserin ( Belviq , Eisai) and phentermine-topiramate ( Qysmia , Vivus), represent "slim pickings" for the treatment of obesity based on the available evidence to ...Dermatology Online Journal, 2 weeks ago Slim pickings for 2 weight-loss drugs? Pharmacy Choice, 1 week ago Diet medications: What to know about weight loss prescription and OTC drugs Examiner.com, 3 weeks ago FDA approves two drugs for long-term weight loss News-Medical.Net, 3 weeks ago
Design, Synthesis, and Pharmacological Evaluation of Fluorinated Tetrahydrouridine Derivatives as Inhibitors of Cytidine Deaminase
Eisai Inc., Baltimore, Maryland 21224, United States‡ Eisai Inc., Andover, Massachusetts 01810, United States§ Brain Science Institute and Department of Neurology, Johns Hopkins University, 855 North Wolfe Street, Suite 231, Baltimore, Maryland ...Journal of Medicinal Chemistry, 1 week ago Eisai files marketing authorization for weight management treatment in Brazil TradingCharts.com, 2 weeks ago Arena Pharma to receive milestone payment as Eisai files Belviq MAA in Brazil PharmaBiz, 3 weeks ago
By a News Reporter-Staff News Editor at Life Science Weekly -- Investigators publish new report on Cytoskeletal Proteins. According to news reporting from Ibaraki, Japan , by NewsRx journalists, research stated, "Basal forebrain cholinergic neurons ...4 Traders, 2 days ago CVS CAREMARK CORPORATION : Eisai Reports Improved Patient Access for BELVIQ® lorcaserin HCI CIV 4 Traders, 2 weeks ago Eisai Reports Improved Patient Access for BELVIQ(R) lorcaserin HCI CIV NewsRX, 2 weeks ago Eisai Inc. Reports Improved Patient Access For BELVIQ® (lorcaserin HCI) CIV BioSpace, 3 weeks ago
Arena Pharmaceuticals and Eisai said Monday that their weight loss drug Belviq will be available to more people thanks to an agreement with pharmacy benefits manager CVS Caremark. The companies said more than half of all Americans with insurance ...BusinessWeek, 3 weeks ago
Eisai Pharmatechnology and Manufacturing Private Ltd, which has a unit in the pharma city at Parawada in Visakhapatnam district, will do its best to spread awareness about filariasis and di...Business Line, 1 month ago Eisai Pharma gets award for CSR activity Business Line, 2 months ago
Arena ( ARNA ) investors are busy today looking at the Eisai quarterly report , crunching keys on calculators, and trying to find that nugget of information that points to how well the anti-obesity drug Belviq is selling. Eisai is the marketing ...Seeking Alpha, 1 month ago Arena Prescription Sales Up: Stops Stock Slide Seeking Alpha, 1 week ago Arena's Belviq Sales To Hit $150 Million In 2014? Seeking Alpha, 1 week ago Arena Falls On Quarterly Results Seeking Alpha, 1 week ago
on your WebpageAdd Widget >Get your members hooked!